May 11, 2022 / 09:00PM GMT
Gregory Allen Harrison - BofA Securities, Research Division - Analyst
Welcome to the afternoon session of Day 2 of the Bank of America Healthcare Conference. My name is Greg Harrison, and I'm one of the biotech analysts here at BofA. I also have Mary Kate Davis from the team here with me. And it's my pleasure today to introduce John Evans, Chief Executive Officer of Beam Therapeutics. John, would you like to start off with some opening remarks, and then we can jump into Q&A?
John M. Evans - Beam Therapeutics Inc. - CEO & Director
Sounds great, Greg. Thanks for having us. It's great to be here this week back in person. So I'm John Evans, CEO of Beam. I've been doing this from the beginning of the company, about 4.5 years now. Before Beam, I was at Agios for several years developing drugs in cancer and rare diseases.
So Beam is a next-generation gene editing company. So we're in the CRISPR field, but we are a newer way of using CRISPR that fixes some of the deficiencies of the previous technology platforms. So I put us in the general category of
Beam Therapeutics Inc at Bank of America Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers